New pathway of atherosclerotic drug therapy - Anti-inflammatory effect

Chinese Pharmacological Bulletin

Volumn 20, Issue 5, 2004, Pages 499-503

  Lin, Rong ^a   Gan, Wei Jie ^a   Liu, Jun Tian ^a  

^a MEDICAL SCHOOL OF XI AN JIAOTONG UNIVERSITY   (China)

Author keywords

Atherosclerosis; Drug; Inflammation

Indexed keywords

ANTIINFLAMMATORY AGENT; C REACTIVE PROTEIN; CD40 ANTIGEN; CD40 LIGAND; CYTOKINE; HYDROLASE; IMMUNOGLOBULIN ENHANCER BINDING PROTEIN;

ANTIINFLAMMATORY ACTIVITY; ARTICLE; ATHEROSCLEROSIS; ATHEROSCLEROTIC PLAQUE; CELL MIGRATION; CELL PROLIFERATION; CELL STIMULATION; CYTOKINE RELEASE; ENDOTHELIUM CELL; INFLAMMATION; MONOCYTE; VASCULAR SMOOTH MUSCLE;

EID: 4043057950     PISSN: 10011978     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (24)

1. Ross R. Atherosclerosis - An inflammatory disease. N Engl J Med, 1999; 340(2): 115-26
2. Pasceri V, Willerson JT, Yeh ETH. Direct proinflammatory effect of C-reative protein on human endothelial cells. Circulation, 2000; 102(18): 2165-8
3. Pasceri V, chang J, Willerson JT et al. Modulation of C-reative protein-mediated moncyte chemoattractant protein-1 induction in human endothelial cells by anti-atherosclerosis drugs. Circulation, 2001; 103(21): 2531-4
4. Edward TH, James T, Willerson JT. Coming of age of C-reative protein. Circulation, 2003; 107(3): 370-2
5. Subodh V, Shu-hong L, Mitesh V et al. Endothelin antagonism and interleckin-6 autenuate the proatherogenic effect of C-reative protein. Circulation, 2002; 105(16): 60-6
6. Schonbeck U, Libby P. CD40 signaling and plaque instability. Circ Res, 2001; 89(12): 1092-3
7. Lutgens E, Daemen MJ. CD40-CD40L interactions in atherosclerosis. Trends Cardiovasc Med, 2002; 12(1): 27-32
8. Schonbeck U, Gerdes N, Varo N et al. Oxidixed low-density lipoprotein augments and 3-hydroxy-3-methlglutary coenzyme A reductase inhibitors limit CD40 and CD40L expression in human vascular cells. Circulation, 2002; 106(23): 2888-939
9. Bruemmer D, Riggers U, Holzmeiser J et al. Expression of CD40 in vascular smooth muscle cells and mcrophages is associated with early development of human atherosclerosis lesions. Am J Cardiol, 2001; 87(1): 21-7
10. Lutgens E, Cleutjens KBJM, Heenerman S et al. Both early and delayed anti-CD40L antibody treatment induced a stable plaque phenotype. Proc Natl Acad Sci USA, 2000; 97(13): 7464-9
11. Wagner AH, Gebauer M, Guldenzoph B et al. 3-hydroxy-3-methlglutary coenzyme A reductase-independent inhibition og CD40 expression by atorvastatin in human endothelial cells. Arteriosclerosis Thrombosis And Vascular Biology, 2002; 22(11): 1784-9
12. Campbell LA, Blessing E, Rosenfeld M et al. Mouse models of C. pneumoniae infection and atherosclerosis. J Infect Dis, 2000; 181(Suppl 3): 508-15
13. Caydos CA. Growth in vascular cells and cytokin production by Chlamydia pneumoniate. J Infect Dis, 2000; 181(Suppl 3): 473-8
14. Ignatius W, Brian C, Esther V et al. De Novo Induction of atherosclerosis by chlamydia pneumoniae in a rabbit model. Infection and Immunity, 1999: 6084-8
15. Freter RR, Alberta JA, Hwang GY et al. Platelet-derived growth factor induction of the immediated-rarly gene MCP-1 is mediated by NF-κB and a 90-kDa phosphoprotein coactivor. J Biol Chem, 1996; 271(29): 17417-24
16. Peng Q, Wei Z, Lau BH. Pycnogenol inhibits tumer necrosis factor-alpha-induced nuclear kappa B activation and adhesion molecule expression in human vascular endothelial cells. Cell Mol Life Sci, 2000; 47(5): 834-42
17. Rodriguez-Porcel M, Leman LO, Hollmes DR et al. Chronic antioxidant supplementation attenuates muclear factor-kappa B activation and preserves endothelial function in hypercholesterolemic pigs. Cardiovasc Res, 2002; 53: 1010-8
18. Dichtl W, Nilsson L, Goncalves I et al. Very low-density lipoprotein activates nuclear factor-κB in endothelial cells. Circ Res, 1999; 84(9): 1085-94
19. Kranzhofer R, Schmidt J, Pfeiffer CA et al. Angiotensin indues inflammatory activation of human vascular smooth muscle cells. Arterioscler Thromb Vasc Biol, 2002; 19(7): 1623-9
20. Ortego M, Buston, Hernandez-presa MA et al. Atorvastatin reduces NF-κB activation and chemokine expression in vascular smooth muscle cells and mononuclear cells. Atherosclerosis, 1999; 147(2): 253-61
21. Hernandez-presa MA, Martin-Ventura JL, Ortego M et al. Atorvasatin reduces the expression of cyclooxygenase-2 in a rabbit model of atherosclerosis and in cultured vascular smooth cells. Atherosclerosis, 2002; 160(1): 147-9
22. Maix N, Sukhova GK, Collins T et al. PPAR alpha activators inhibit cytokine-induced vascular cell adhension molecule-1 expression in human endothelial cell. Circulation, 1999; 99(24): 3125-31